Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early Administration of Latency Reversing Therapy and Broadly Neutralizing Antibodies to Limit the Establishment of the HIV-1 Reservoir During Initiation of Antiretroviral Treatment - a Randomized Controlled Trial

NCT03041012 is registered in ClinicalTrials.gov with Aarhus University Hospital as lead sponsor.

NCT NCT03041012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03041012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early Administration of Latency Reversing Therapy and Broadly Neutralizing Antibodies to Limit the Establishment of the HIV-1 Reservoir During Initiation of Antiretroviral Treatment - a Randomized Controlled Trial
Lead sponsor
Aarhus University Hospital
Phase
Phase 2
Overall status
Completed
Start date
January 20, 2017
Completion date
December 30, 2022
Enrollment
60 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

hiv